UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 103

Sortiert nach

Impact of postprandial glycaemia on health and prevention of disease

Obesity reviews, 2012-10, Vol.13 (10), p.923-984

2012

Volltextzugriff (PDF)

GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study

Diabetes (New York, N.Y.), 2015-07, Vol.64 (7), p.2513-2525

2015

Volltextzugriff (PDF)

Proteomics reveals the effects of sustained weight loss on the human plasma proteome

Molecular systems biology, 2016-12, Vol.12 (12), p.901-n/a

2016

Volltextzugriff (PDF)

An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future

Diabetes, obesity & metabolism, 2011-05, Vol.13 (5), p.394-407

2011

Volltextzugriff (PDF)

Fat-Secreted Ceramides Regulate Vascular Redox State and Influence Outcomes in Patients With Cardiovascular Disease

Journal of the American College of Cardiology, 2021-05, Vol.77 (20), p.2494-2513

2021

Volltextzugriff (PDF)

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential

Obesity reviews, 2011-08, Vol.12 (8), p.593-601

2011

Volltextzugriff (PDF)

A Functional Amino Acid Substitution in the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Gene Is Associated With Lower Bone Mineral Density and Increased Fracture Risk

The journal of clinical endocrinology and metabolism, 2014-04, Vol.99 (4), p.E729-E733

2014

Volltextzugriff (PDF)

Evidence of a liver–alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids

Diabetologia, 2018-03, Vol.61 (3), p.671-680

2018

Volltextzugriff (PDF)

Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss

International Journal of Obesity, 2015-05, Vol.39 (5), p.834-841

2015

Volltextzugriff (PDF)

Low Physical Activity Accentuates the Effect of the FTO rs9939609 Polymorphism on Body Fat Accumulation

Diabetes (New York, N.Y.), 2008-01, Vol.57 (1), p.95-101

2008

Volltextzugriff (PDF)

Endocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity

Journal of endocrinological investigation, 2024-05, Vol.47 (5), p.1289-1294

2024

Volltextzugriff (PDF)

KCNQ1 Long QT Syndrome Patients Have Hyperinsulinemia and Symptomatic Hypoglycemia

Diabetes (New York, N.Y.), 2014-04, Vol.63 (4), p.1315-1325

2014

Volltextzugriff (PDF)

Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial

Cardiovascular diabetology, 2023-02, Vol.22 (1), p.41-12, Article 41

2023

Volltextzugriff (PDF)

Age-dependent transition from islet insulin hypersecretion to hyposecretion in mice with the long QT-syndrome loss-of-function mutation Kcnq1-A340V

Scientific reports, 2021-06, Vol.11 (1), p.12253-12253, Article 12253

2021

Volltextzugriff (PDF)

Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass

Journal of bone and mineral metabolism, 2020, Vol.38 (1), p.117-125

2020

Volltextzugriff (PDF)

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report

Cell reports. Medicine, 2020-04, Vol.1 (1), p.100006, Article 100006

2020

Volltextzugriff (PDF)

Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

Cardiovascular diabetology, 2019-10, Vol.18 (1), p.130-130, Article 130

2019

Volltextzugriff (PDF)

Health care professionals from developing countries report educational benefits after an online diabetes course

BMC medical education, 2017-05, Vol.17 (1), p.97-97, Article 97

2017

Volltextzugriff (PDF)

Gain-of-function mutation in the voltage-gated potassium channel gene KCNQ1 and glucose-stimulated hypoinsulinemia - case report

BMC endocrine disorders, 2020-03, Vol.20 (1), p.38-38, Article 38

2020

Volltextzugriff (PDF)

Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system

International Journal of Obesity, 2017-08, Vol.41 (8), p.1263-1270

2017

Volltextzugriff (PDF)

Genome-wide association study of circulating levels of glucagon during an oral glucose tolerance test

BMC medical genomics, 2021-01, Vol.14 (1), p.3-7, Article 3

2021

Volltextzugriff (PDF)

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

The New England journal of medicine, 2021-05, Vol.384 (18), p.1719-1730

2021

Volltextzugriff (PDF)

Glucose ingestion causes cardiac repolarization disturbances in type 1 Long QT syndrome patients and healthy subjects

Heart rhythm, 2017-08, Vol.14 (8), p.1165-1170

2017

Volltextzugriff (PDF)

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. Reply

The New England journal of medicine, 2021-08, Vol.385 (6), p.573-574

2021

Volltextzugriff (PDF)

1 – 25 von 103

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(95)
Mit Volltextzugriff
(99)

Publikationsform

Artikel
(103)

Sprache

Englisch
(102)
Japanisch
(10)
Dänisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Impact of postprandial glycaemia on health and prevention of disease

GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study

Proteomics reveals the effects of sustained weight loss on the human plasma proteome

An overview of once-weekly glucagon-like peptide-1 receptor agonists-available efficacy and safety data and perspectives for the future

Fat-Secreted Ceramides Regulate Vascular Redox State and Influence Outcomes in Patients With Cardiovascular Disease

Obesity - an indication for GLP-1 treatment? Obesity pathophysiology and GLP-1 treatment potential

A Functional Amino Acid Substitution in the Glucose-Dependent Insulinotropic Polypeptide Receptor (GIPR) Gene Is Associated With Lower Bone Mineral Density and Increased Fracture Risk

Evidence of a liver–alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids

Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss

Low Physical Activity Accentuates the Effect of the FTO rs9939609 Polymorphism on Body Fat Accumulation

Endocannabinoid-related molecules predict the metabolic efficacy of GLP-1 receptor agonism in humans with obesity

KCNQ1 Long QT Syndrome Patients Have Hyperinsulinemia and Symptomatic Hypoglycemia

Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity, and inflammation: a randomized controlled trial

Age-dependent transition from islet insulin hypersecretion to hyposecretion in mice with the long QT-syndrome loss-of-function mutation Kcnq1-A340V

Protocol for a single-centre, parallel-group, randomised, controlled, superiority trial on the effects of time-restricted eating on body weight, behaviour and metabolism in individuals at high risk of type 2 diabetes: the REStricted Eating Time (RESET) study

Adults with pathogenic MC4R mutations have increased final height and thereby increased bone mass

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report

Greater glucagon-like peptide-1 responses to oral glucose are associated with lower central and peripheral blood pressures

Health care professionals from developing countries report educational benefits after an online diabetes course

Gain-of-function mutation in the voltage-gated potassium channel gene KCNQ1 and glucose-stimulated hypoinsulinemia - case report

Chronic intrahypothalamic rather than subcutaneous liraglutide treatment reduces body weight gain and stimulates the melanocortin receptor system

Genome-wide association study of circulating levels of glucagon during an oral glucose tolerance test

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined

Glucose ingestion causes cardiac repolarization disturbances in type 1 Long QT syndrome patients and healthy subjects

Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined. Reply

Suchergebnisse filtern